NewAmsterdam Pharma Company NV（NAMS）价格预测NAMSNewAmsterdam Pharma Company NV

Alphio's NAMS stock price prediction model matches the current NewAmsterdam Pharma Company NV tape against historical breakout patterns, then publishes 1-day and 1-week targets first. The 1-day print is $21.28 (-0.96%). The 1-week path is $21.51 (+0.10%). Longer windows use the same pattern set plus seasonality; the 1-month and multi-year forecasts sit behind unlock because they include precise min / avg / max bands.

NewAmsterdam Pharma is not a good buy right now due to significant financial losses and negative market sentiment. The stock is currently priced at $19.83, down 43.66% year-to-date, and has an RSI of 25.93, indicating it is oversold. The company reported a net loss of $64.1 million in Q2 2026, a substantial increase from previous losses, which raises concerns about its financial health and market competitiveness. Additionally, insider selling has increased by 113.69%, suggesting a lack of confidence from those closest to the company. The main risk is the forward P/E ratio of 119.05, indicating high valuation expectations that may not be met given the current financial performance.

NewAmsterdam Pharma Company NV (NAMS) last closed at $21.49, losing -0.05%. These facts feed the 1-day and 1-week NAMS price prediction above.